Person Closely Associated
Dealing
Oxford, UK - 30 April 2025: OXB (LSE: OXB) (the "Company"), a global quality and
innovation-led cell and gene therapy CDMO, today announces that
Pippa Radcliffe, a person closely associated with
Dr. Kyriacos Mitrophanous, Chief Innovation Officer of the Company,
exercised 1,209 options at nil exercise price and disposed
1,209 shares at £2.9785 per share on 30 April 2025.
The below notifications, made in
accordance with the requirements of the EU Market Abuse Regulation,
give further details of the transaction.
|
1.
|
Details of the Person Discharging Managerial
Responsibility ("PDMR")/person closely associated with them
("PCA")
|
|
a)
|
Name
|
Pippa Radcliffe
|
|
2.
|
Reason for the notification
|
|
a)
|
Position/status
|
This notification concerns Pippa
Radcliffe in her capacity as a person closely associated with a
person discharging managerial responsibilities. The person
discharging managerial responsibilities is Dr. Kyriacos
Mitrophanous, Chief Innovation Officer of the Company. The
association arises by virtue of Pippa Radcliffe being the spouse of
Dr. Kyriacos Mitrophanous.
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the Issuer
|
|
a)
|
Full name of the entity
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Date of the transaction
|
2025-04-30
|
|
b)
|
Description of the financial
instrument
|
Ordinary Shares of 50 pence
each
|
|
c)
|
Identification code
|
ISIN: GB00BDFBVT43
|
|
d)
|
Nature of the transaction
|
Exercise of Options at nil exercise
price
|
|
e)
|
Place of the transaction
|
London Stock Exchange, Main Market
(XLON)
|
|
f)
|
Currency
|
GBP - British pound
|
|
g)
|
Price(s) and volumes(s)
|
|
Price(s)
|
Volume(s)
|
|
£0.00
|
1,209
|
|
|
h)
|
Aggregated information
-
Aggregate volume
-
Price
-
Aggregated total
|
1,209
£0.00
£0.00
|
|
1.
|
Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them
("PCA")
|
|
a)
|
Name
|
Pippa Radcliffe
|
|
2.
|
Reason for the notification
|
|
a)
|
Position/status
|
This notification concerns Pippa
Radcliffe in her capacity as a person closely associated with a
person discharging managerial responsibilities. The person
discharging managerial responsibilities is Dr. Kyriacos
Mitrophanous, Chief Innovation Officer of the Company. The
association arises by virtue of Pippa Radcliffe being the spouse of
Dr. Kyriacos Mitrophanous.
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Date of the transaction
|
2025-04-30
|
|
b)
|
Description of the financial
instrument
|
Ordinary Shares of 50 pence
each
|
|
c)
|
Identification code
|
ISIN: GB00BDFBVT43
|
|
d)
|
Nature of transaction
|
Sale of
shares
|
|
e)
|
Place of the transaction
|
London Stock Exchange, Main Market
(XLON)
|
|
f)
|
Currency
|
GBP - British pound
|
|
g)
|
Price(s) and volumes(s)
|
|
Price(s)
|
Volume(s)
|
|
£2.9785
|
1,209
|
|
|
h)
|
Aggregated information
-
Aggregate volume
-
Price
-
Aggregated total
|
1,209
£2.9785
£3,601.01
|
-Ends-
Enquiries:
OXB:
Natalie Walter, Company Secretary -
T: +44 (0) 1865 783 000 / E:
cosec@oxb.com
ICR
Healthcare:
T: +44 (0)20 3709 5700 /
E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray /
Davide Salvi
About OXB
OXB (LSE: OXB) is a
global quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell
and gene therapy, OXB has
30 years of experience in
viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing
viral vector development and manufacturing
expertise in lentivirus, adeno-associated virus (AAV), adenovirus
and other viral vector types. OXB's world-class capabilities span
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems,
analytical methods and depth of regulatory
expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the TetraVecta™ system), dual plasmid system
for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging
cell lines.
OXB, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has bioprocessing and manufacturing
facilities across Oxfordshire, UK, Lyon and Strasbourg, France and
near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn
and YouTube.
